Key Drivers
- Strong cash reserve
- High cash burn
- No revenue
AIAI Summary
BBOT has shifted from a financing-run biotech to a milestone-driven oncology bet—its >$370M runway and early differentiated RAS signals (PDAC PR for BBO‑11818; high ORR for BBO‑8520) make upcoming AACR/late-cohort readouts the primary value drivers, so treat it as an opportunistic trade sized against binary clinical catalysts. Watch confirmatory efficacy/durability and liver-toxicity in larger cohorts (and monitor burn vs. trial timelines) because replication or safety setbacks will rapidly reintroduce dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash reserve
- •High cash burn
- •No revenue
BBOT has very strong liquidity and minimal debt but no revenue, heavy opex/R&D burn causing large negative cash flow and losses, and is reliant on external financing to sustain operations.
Price Behavior
Key Price Behavior Insights:
- •Below short MA
- •Support breach
- •Elevated downside
Price fell ~13% over the last month, trading below the short MA (~$9.77) and breaching the key ~$9.00 support on 2026-03-20, signaling short-term bearish momentum with resistance at $10.20–$10.50 and $12–$13 capping any rally.
~13% drop and decisive breach of $9.00 support on 2026-03-20 indicating increased short-term downside risk
Sentiment & News
Key News Insights:
- •PDAC partial response
- •pan‑KRAS preclinical
- •favorable safety signals
BridgeBio's BBOT reported March 2026 RAS-program progress: BBO-11818 delivered a PDAC partial response with strong preclinical pan‑KRAS data, BBO-8520 showed differentiated safety/efficacy including combo promise, and BBO-10203 lacked hyperglycemia signals ahead of AACR disclosures.
Early clinical and preclinical wins should bolster investor confidence and may drive upside ahead of AACR data updates
Similar Companies in Healthcare
Other companies in the same sector with AI ratings